Sun et al. showed that hyperoside inhibits cell viability and increases apoptosis and caspase-3 activity in toll-like receptor 4 (TLR4)-positive breast cancer MDA-MB-231 cells, enhancing the sensitivity of such cells to paclitaxel [29]. Here, TLR4 is linked to breast cancer.